Form 8-K - Current report:
SEC Accession No. 0001193125-25-009595
Filing Date
2025-01-21
Accepted
2025-01-21 16:52:22
Documents
14
Period of Report
2025-01-17
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d926991d8k.htm   iXBRL 8-K 29004
2 EX-3.1 d926991dex31.htm EX-3.1 7820
  Complete submission text file 0001193125-25-009595.txt   173812

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA inkt-20250117.xsd EX-101.SCH 2878
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE inkt-20250117_lab.xml EX-101.LAB 20246
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inkt-20250117_pre.xml EX-101.PRE 12621
16 EXTRACTED XBRL INSTANCE DOCUMENT d926991d8k_htm.xml XML 4099
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Filer) CIK: 0001840229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40908 | Film No.: 25543091
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)